0001819133 2026-08-11 2026-08-11 0001819133 1 2026-08-11 2026-08-11 0001819133 1 2026-08-11 2026-08-11 0001819133 2 2026-08-11 2026-08-11 iso4217:USD pure S-3 424B5 EX-FILING FEES 333-291684 0001819133 Tango Therapeutics, Inc. N/A true false S-3 Tango Therapeutics, Inc. false Equity Common Stock, par value $0.001 per share true 400000000.00 0.0001381 55240.00 400000000.00 55240.00 0.00 4917.80 50322.20 1 The registration fee is calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended (the "Securities Act"), based on the proposed maximum aggregate offering price, and Rule 457(r) under the Securities Act. In accordance with Rules 456(b) and 457(r) under the Securities Act, the registrant initially deferred payment of all of the registration fee for its Registration Statement on Form S-3ASR (Registration No. 333-291684) (the "Registration Statement"), which was filed with the Securities and Exchange Commission on November 21, 2025. Pursuant to Rule 457(p) under the Securities Act, the registrant hereby applies $4,917.80 of the registration fee previously paid in connection with the Prior Registration Statement (as defined below) to offset the registration fees that are payable in connection with the registration of securities on this prospectus supplement. true Tango Therapeutics, Inc. S-3 333-291684 2025-11-21 4917.80 Equity Common Stock, par value $0.001 per share 35610433.97 true Tango Therapeutics, Inc. S-3 333-287202 2025-05-12 28146.10 On November 21, 2025, the registrant filed the Registration Statement, which includes a sales agreement prospectus supplement covering the offering, issuance and sale by the registrant of up to an aggregate of $100,000,000 of its common stock pursuant to its "at-the-market" offering program (the "Prior Prospectus Supplement"). The registrant incurred a filing fee in the amount of $13,810.00 in connection with the Prior Prospectus Supplement, which fee was calculated pursuant to Rule 457(o) under the Securities Act and offset by the fees paid in connection with the registrant's registration statement on Form S-3 filed on May 12, 2025 (File No. 333-287202) (the "Prior Registration Statement"). As of the date of filing of this prospectus supplement, $35,610,433.97 of shares of the registrant's common stock (the "Unsold Securities") remained unsold under the Prior Prospectus Supplement. Pursuant to Rule 457(p) under the Securities Act, filing fees in the amount of $4,917.80 relating to the Unsold Securities are being carried forward, and the offering pursuant to the Prior Prospectus Supplement is deemed terminated. 400000000.00 true